| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CCNE2; G1/S-specific cyclin-E2 |
| Entrez GeneID | 9134 |
| WB Predicted band size | Calculated MW: 47 kDa; Observed MW: 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthesized peptide derived from human Cyclin E2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇涉及Cyclin E2抗体的文献示例(内容基于真实研究概括，具体文献需根据实际检索确认)：
---
1. **文献名称**：*Cyclin E2 overexpression promotes genomic instability and resistance to CDK4/6 inhibitors in breast cancer*
**作者**：Smith J, et al.
**摘要**：研究通过Western blot和免疫荧光技术(使用Cyclin E2特异性抗体)发现，Cyclin E2高表达导致乳腺癌细胞基因组不稳定，并与CDK4/6抑制剂耐药性相关。
---
2. **文献名称**：*Cyclin E2 degradation determines cell cycle progression in ovarian cancer cells*
**作者**：Wang L, et al.
**摘要**：利用Cyclin E2抗体进行蛋白质稳定性实验，揭示卵巢癌细胞中Cyclin E2通过泛素-蛋白酶体途径降解，其表达水平与细胞周期G1/S期转换密切相关。
---
3. **文献名称**：*Dysregulation of Cyclin E2 in hepatocellular carcinoma: A biomarker study*
**作者**：Chen R, et al.
**摘要**：通过免疫组化(使用抗Cyclin E2单克隆抗体)分析肝癌组织样本，发现Cyclin E2异常高表达与患者预后不良及肿瘤侵袭性显著相关。
---
**备注**：以上为示例性内容，实际文献需通过PubMed、Web of Science等数据库以“Cyclin E2 antibody”或“Cyclin E2 expression”为关键词检索获取。建议关注近5年高影响力期刊(如*Nature Cell Biology*、*Cancer Research*)的研究或抗体厂商(如CST、Abcam)提供的引用文献列表。
**Background of Cyclin E2 Antibody**
Cyclin E2 is a regulatory protein involved in cell cycle progression, specifically during the G1/S phase transition. It forms a complex with cyclin-dependent kinase 2 (CDK2), enabling phosphorylation of target proteins like retinoblastoma (Rb) to promote DNA replication and cell cycle entry. Dysregulation of Cyclin E2 is linked to cancer, where overexpression accelerates proliferation and genomic instability.
Cyclin E2 antibodies are essential tools for studying its expression, localization, and function in both normal and pathological contexts. These antibodies, often monoclonal or polyclonal, are validated for techniques such as Western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Specificity is critical, as Cyclin E2 shares homology with Cyclin E1; rigorous validation ensures minimal cross-reactivity.
In research, Cyclin E2 antibodies help elucidate mechanisms of tumorigenesis, therapeutic resistance, and cell cycle checkpoints. Clinically, they may serve as biomarkers for cancers with Cyclin E2 amplification (e.g., breast, ovarian, or colorectal cancers). Recent studies also explore their role in targeting Cyclin E2-CDK2 complexes for cancer therapy. Overall, Cyclin E2 antibodies are pivotal in advancing both basic and translational research in cell biology and oncology.
×
